DrugPatentWatch Database Preview
Litigation Details for In re ACTOS Antitrust Litigation (S.D.N.Y. 2013)
» See Plans and Pricing
In re ACTOS Antitrust Litigation (S.D.N.Y. 2013)
| Docket | Start Trial | Date Filed | 2013-12-30 |
| Court | District Court, S.D. New York | Date Terminated | 2015-09-24 |
| Cause | 28:1332bc Diversity-Breach of Contract | Assigned To | Ronnie Abrams |
| Jury Demand | Plaintiff | Referred To | Stewart D. Aaron |
| Patents | 6,329,404 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in In re ACTOS Antitrust Litigation
The small molecule drugs covered by the patent cited in this case are Start Trial , Start Trial , Start Trial , Start Trial , and Start Trial .
Details for In re ACTOS Antitrust Litigation (S.D.N.Y. 2013)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-09-22 | 221 | (“584 patent”) and 6,329,404 (“404 patent”). 'l`he 584 and 404 patents also claimed methods of using…submitted patent information for the 584 and 404 patents, describing them as drug product patents claiming…the 584 and 404 patents in the Orange Book as “drug product patents” because those patents did “not claim…brand’s patents. Any ANDA submitted must contain “an appropriate certification for each listed patent.” 21…product Where there are no applicable patents, or the patents have expired or will expire prior to the | External link to document | |
| 2018-03-14 | 255 | and 6,329,404 (the “’404 Patent”)—claim the ACTOS drug product. These patents plainly and unambiguously…its patent information that the two patents—United States Patent Nos. 5,965,584 (the “’584 Patent”) and…the ’777 Patent, the ’584 Patent, and the ’404 Patent, Takeda submitted eight other patents to the FDA…the ’584 Patent and the ’404 Patent as drug- product patents claiming ACTOS only if the patents in fact…improper patent information describing the ’584 Patent and ’404 Patent as drug product patents for ACTOS | External link to document | |
| 2019-09-30 | 272 | Memorandum & Opinion | other patents—U.S. Patent Nos. 5,965,584 (the “’584 patent”) and 6,329,404 (the “’404 patent”)—which… “[p]rocess patents, patents claiming packaging, patents claiming metabolites, and patents claiming intermediates… several patents related to its diabetes medicines. The first of those patents, U.S. Patent. No. 4,687,777…hereinafter “the Patents”) as both drug product patents and method- of-use patents (and improperly so, in…describe the Patents exactly as it did—that is, as both drug product patents and method-of-use patents for the | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
